drugset / Trial / NCT02429388

High-Dose Aldactone for Treatment of Diuretic Resistant Heart Failure

NCT02429388

RandomizedParallel-groupOpen-labelTreatment

Summary

Prospective, open-label, randomized cohort study comparing adding high-dose spironolactone to usual heart failure care versus usual care in patients with acute decompensated heart failure. Patients will be randomized in a 1:1 fashion to either usual care or high-dose spironolactone plus usual care. Both arms of the study will continue with treatment of ADHF until euvolemia as defined as the resolution of pulmonary edema, peripheral edema, abdominal bloating and/or jugular venous distention. Assessment of clinical status and serum electrolytes, symptoms and renal function will be performed in accordance to standard of care.

Timeline

Start
2014-05
Primary completion
2015-10
Completion
2015-10

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Spironolactone Small molecule 100 mg Oral

Indications